{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:39:09Z","timestamp":1785321549741,"version":"3.55.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["CA156700"],"award-info":[{"award-number":["CA156700"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"George Whipple Professorship Endowment"},{"name":"Taiwan Ministry of Health"},{"name":"Welfare Clinical Trial and Research Center of Excellence","award":["MOHW104-TDU-B-212-113002"],"award-info":[{"award-number":["MOHW104-TDU-B-212-113002"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81630019"],"award-info":[{"award-number":["81630019"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province, China","doi-asserted-by":"publisher","award":["2017A030313800"],"award-info":[{"award-number":["2017A030313800"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.canlet.2018.11.008","type":"journal-article","created":{"date-parts":[[2018,11,10]],"date-time":"2018-11-10T17:30:41Z","timestamp":1541871041000},"page":"483-490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Targeting AR-Beclin 1 complex-modulated growth factor signaling increases the antiandrogen Enzalutamide sensitivity to better suppress the castration-resistant prostate cancer growth"],"prefix":"10.1016","volume":"442","author":[{"given":"Meng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaozhao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chawnshang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2018.11.008_bib1","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/bjc.2017.337","article-title":"IGF-1R associates with adverse outcomes after radical radiotherapy for prostate cancer","volume":"117","author":"Aleksic","year":"2017","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.canlet.2018.11.008_bib2","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2018.11.008_bib3","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2018.11.008_bib4","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","article-title":"Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade","volume":"155","author":"Arora","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2018.11.008_bib5","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature22078","article-title":"Polyglutamine tracts regulate beclin 1-dependent autophagy","volume":"545","author":"Ashkenazi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2018.11.008_bib6","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2018.11.008_bib7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2013.08.020","article-title":"Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone","volume":"50","author":"Bianchini","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2018.11.008_bib8","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","article-title":"Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer","volume":"19","author":"Carver","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2018.11.008_bib9","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1093\/nar\/22.15.3181","article-title":"The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function","volume":"22","author":"Chamberlain","year":"1994","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.canlet.2018.11.008_bib10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.canlet.2017.08.014","article-title":"Androgen-deprivation therapy with enzalutamide enhances prostate cancer metastasis via decreasing the EPHB6 suppressor expression","volume":"408","author":"Chen","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2018.11.008_bib11","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1172\/JCI73214","article-title":"Disrupting SUMOylation enhances transcriptional function and ameliorates polyglutamine androgen receptor-mediated disease","volume":"125","author":"Chua","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2018.11.008_bib12","first-page":"3438","article-title":"Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer","volume":"8","author":"Di Lorenzo","year":"2002","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2018.11.008_bib13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s12032-012-0355-0","article-title":"Low expression of Beclin 1 and elevated expression of HIF-1alpha refine distant metastasis risk and predict poor prognosis of ER-positive, HER2-negative breast cancer","volume":"30","author":"Dong","year":"2013","journal-title":"Med. Oncol."},{"key":"10.1016\/j.canlet.2018.11.008_bib14","doi-asserted-by":"crossref","first-page":"378","DOI":"10.4103\/1008-682X.122876","article-title":"PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance","volume":"16","author":"Edlind","year":"2014","journal-title":"Asian J. Androl."},{"key":"10.1016\/j.canlet.2018.11.008_bib15","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/2159-8290.CD-13-0226","article-title":"A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509","volume":"3","author":"Joseph","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2018.11.008_bib16","doi-asserted-by":"crossref","first-page":"22284","DOI":"10.1074\/jbc.273.35.22284","article-title":"Apg14p and Apg6\/Vps30p form a protein complex essential for autophagy in the yeast, Saccharomyces cerevisiae","volume":"273","author":"Kametaka","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2018.11.008_bib17","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1158\/1078-0432.CCR-15-2119","article-title":"Cotargeting androgen receptor splice variants and mTOR signaling pathway for the treatment of castration-resistant prostate cancer","volume":"22","author":"Kato","year":"2016","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2018.11.008_bib18","doi-asserted-by":"crossref","first-page":"11612","DOI":"10.1038\/ncomms11612","article-title":"Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer","volume":"7","author":"Kaushik","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2018.11.008_bib19","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/2159-8290.CD-13-0142","article-title":"An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide)","volume":"3","author":"Korpal","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2018.11.008_bib20","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1158\/1541-7786.MCR-17-0614","article-title":"ONC201 targets AR and AR-V7 signaling, reduces PSA, and synergizes with everolimus in prostate cancer","volume":"16","author":"Lev","year":"2018","journal-title":"Mol. Canc. Res."},{"key":"10.1016\/j.canlet.2018.11.008_bib21","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3892\/br.2013.171","article-title":"Roles of autophagy-related genes Beclin-1 and LC3 in the development and progression of prostate cancer and benign prostatic hyperplasia","volume":"1","author":"Liu","year":"2013","journal-title":"Biomedical reports"},{"key":"10.1016\/j.canlet.2018.11.008_bib22","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.juro.2016.06.095","article-title":"A whole blood assay for AR-V7 and AR(v567es) in patients with prostate cancer","volume":"196","author":"Liu","year":"2016","journal-title":"J. Urol."},{"key":"10.1016\/j.canlet.2018.11.008_bib23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jmoldx.2016.08.003","article-title":"Analytical Validation of androgen receptor splice variant 7 detection in a clinical laboratory improvement Amendments (CLIA) laboratory setting","volume":"19","author":"Lokhandwala","year":"2017","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.canlet.2018.11.008_bib24","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/ijc.31237","article-title":"Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models","volume":"142","author":"Luo","year":"2018","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.canlet.2018.11.008_bib25","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1158\/1535-7163.MCT-14-1057","article-title":"NF-kappaB2\/p52:c-Myc:hnRNPA1 pathway regulates expression of androgen receptor splice variants and enzalutamide sensitivity in prostate cancer","volume":"14","author":"Nadiminty","year":"2015","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.canlet.2018.11.008_bib26","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/pros.23501","article-title":"AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients","volume":"78","author":"Okegawa","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2018.11.008_bib27","doi-asserted-by":"crossref","first-page":"41976","DOI":"10.18632\/oncotarget.5659","article-title":"Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer","volume":"6","author":"Qi","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2018.11.008_bib28","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.molcel.2017.01.027","article-title":"Phosphoglycerate kinase 1 phosphorylates Beclin1 to induce autophagy","volume":"65","author":"Qian","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2018.11.008_bib29","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1172\/JCI20039","article-title":"Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene","volume":"112","author":"Qu","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2018.11.008_bib30","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1038\/onc.2014.454","article-title":"Beclin 1 regulates growth factor receptor signaling in breast cancer","volume":"34","author":"Rohatgi","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2018.11.008_bib31","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2018.11.008_bib32","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/jamaoncol.2016.1828","article-title":"Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer","volume":"2","author":"Scher","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.canlet.2018.11.008_bib33","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1083\/jcb.137.1.79","article-title":"Endosome to Golgi retrieval of the vacuolar protein sorting receptor, Vps10p, requires the function of the VPS29, VPS30, and VPS35 gene products","volume":"137","author":"Seaman","year":"1997","journal-title":"JCB (J. Cell Biol.)"},{"key":"10.1016\/j.canlet.2018.11.008_bib34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"Ca - Cancer J. Clin."},{"key":"10.1016\/j.canlet.2018.11.008_bib35","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1158\/1535-7163.MCT-13-0032","article-title":"Synergistic targeting of PI3K\/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo","volume":"12","author":"Thomas","year":"2013","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.canlet.2018.11.008_bib36","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.eururo.2014.08.006","article-title":"Combination AZD5363 with enzalutamide significantly delays enzalutamide-resistant prostate cancer in preclinical models","volume":"67","author":"Toren","year":"2015","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2018.11.008_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152861","article-title":"Combined AKT and MEK pathway blockade in pre-clinical models of enzalutamide-resistant prostate cancer","volume":"11","author":"Toren","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.canlet.2018.11.008_bib38","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.canlet.2018.11.008_bib39","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1073\/pnas.1717800115","article-title":"Increased autophagy blocks HER2-mediated breast tumorigenesis","volume":"115","author":"Vega-Rubin-de-Celis","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2018.11.008_bib40","article-title":"Aberrant expression of Beclin-1 and LC3 correlates with poor prognosis of human hypopharyngeal squamous cell carcinoma","volume":"8","author":"Wang","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.canlet.2018.11.008_bib41","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.canlet.2016.05.018","article-title":"ASC-J9 \u00ae; suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L","volume":"379","author":"Wang","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2018.11.008_bib42","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.eururo.2017.04.005","article-title":"Preclinical study using Malat1 small interfering RNA or androgen receptor splicing variant 7 degradation enhancer ASC-J9((R)) to suppress enzalutamide-resistant prostate cancer progression","volume":"72","author":"Wang","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2018.11.008_bib43","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1748-717X-7-66","article-title":"The prognostic value of expression of HIF1alpha, EGFR and VEGF-A, in localized prostate cancer for intermediate- and high-risk patients treated with radiation therapy with or without androgen deprivation therapy","volume":"7","author":"Weber","year":"2012","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.canlet.2018.11.008_bib44","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.cell.2013.08.015","article-title":"EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance","volume":"154","author":"Wei","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2018.11.008_bib45","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/nm1547","article-title":"ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor","volume":"13","author":"Yang","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2018.11.008_bib46","doi-asserted-by":"crossref","first-page":"15077","DOI":"10.1073\/pnas.2436255100","article-title":"Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor","volume":"100","author":"Yue","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383518306724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383518306724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T10:18:24Z","timestamp":1545819504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383518306724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":46,"alternative-id":["S0304383518306724"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2018.11.008","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting AR-Beclin 1 complex-modulated growth factor signaling increases the antiandrogen Enzalutamide sensitivity to better suppress the castration-resistant prostate cancer growth","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2018.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}